Cargando…

PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy

SIMPLE SUMMARY: The use of checkpoint antibodies has revolutionized the treatment of cancer. Tumor-infiltrating T cells, key mediators of anti-tumor immune responses, are often actively silenced by the tumor microenvironment. Checkpoint antibodies block inhibitory signals or enhance positive signali...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wright, Quentin, Gonzalez Cruz, Jazmina L., Wells, James W., Leggatt, Graham R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269268/ https://www.ncbi.nlm.nih.gov/pubmed/34282763 http://dx.doi.org/10.3390/cancers13133310

Ejemplares similares

Investigating T Cell Immunity in Cancer: Achievements and Prospects
por: Zeng, Zhen, et al.
Publicado: (2021)

NKT cell-targeted vaccination plus anti-4–1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma
por: Kobayashi, Takumi, et al.
Publicado: (2015)

The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma and their relationship with PD-1 expression
por: Choi, Jae Won, et al.
Publicado: (2020)

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
por: Clingan, Philip, et al.
Publicado: (2023)

Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage
por: Tuong, Zewen K., et al.
Publicado: (2019)

Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
por: Tay, Ban Qi, et al.
Publicado: (2021)

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
por: Falchook, Gerald S., et al.
Publicado: (2016)

Bacillus anthracis Protective Antigen Shows High Specificity for a UV Induced Mouse Model of Cutaneous Squamous Cell Carcinoma
por: Crawford, Theo, et al.
Publicado: (2019)

Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients
por: Linedale, Richard, et al.
Publicado: (2017)

Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
por: Furkert, Chris, et al.
Publicado: (2023)

PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Yakobson, Alexander, et al.
Publicado: (2023)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
por: He, Hai-Xia, et al.
Publicado: (2021)

Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey
por: Samaran, Quentin, et al.
Publicado: (2022)

An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation
por: Muik, Alexander, et al.
Publicado: (2022)

PD-1 abrogates the prolonged persistence of CD8(+) CAR-T cells with 4-1BB co-stimulation
por: Li, Feng, et al.
Publicado: (2020)

CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
por: Nishida, Haruto, et al.
Publicado: (2023)

Agonistic nanobodies and antibodies to human VISTA
por: Ma, Yu-Heng Vivian, et al.
Publicado: (2021)

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

IFN-γ Critically Enables the Intratumoural Infiltration of CXCR3(+) CD8(+) T Cells to Drive Squamous Cell Carcinoma Regression
por: Zeng, Zhen, et al.
Publicado: (2021)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
por: Peper-Gabriel, Janet K., et al.
Publicado: (2022)

4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody
por: Cheng, Kang, et al.
Publicado: (2023)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
por: Lu, Di, et al.
Publicado: (2019)

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
por: Phillips, Darci, et al.
Publicado: (2021)

The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
por: Fu, Jing, et al.
Publicado: (2023)

Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma
por: Yülek, Özden, et al.
Publicado: (2022)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
por: Ascierto, Paolo A, et al.
Publicado: (2022)

Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab
por: Cristancho, Cagney, et al.
Publicado: (2020)

PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma
por: Zeng, Qingyu, et al.
Publicado: (2022)

Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy
por: Koukourakis, Ioannis M., et al.
Publicado: (2021)

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
por: Alloghbi, Abdurahman, et al.
Publicado: (2021)

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014)

An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
por: Cheng, Lian-sheng, et al.
Publicado: (2023)

Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities
por: Kaviani, Elina, et al.
Publicado: (2022)

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
por: Gao, Yumei, et al.
Publicado: (2023)

HPV16-E7 Expression in Squamous Epithelium Creates a Local Immune Suppressive Environment via CCL2- and CCL5- Mediated Recruitment of Mast Cells
por: Bergot, Anne-Sophie, et al.
Publicado: (2014)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses
por: Leggatt, Graham R.
Publicado: (2014)

Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies
por: Madireddi, Shravan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_frv26351anhkqj31aag86qookn